Efficacy and Safety Study of SUNPG1623

Active Psoriatic Arthritis Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis

Status Completed

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02980692
Study type	Interventional
Source	Sun Pharmaceutical Industries Limited
Contact
Status	Completed
Phase	Phase 2
Start date	April 19, 2017
Completion date	September 24, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03357471` - Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	Phase 3
Recruiting	`NCT04314544` - Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)	Phase 3
Active, not recruiting	`NCT04314531` - Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)	Phase 3
Withdrawn	`NCT05499416` - Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis	Phase 4
Recruiting	`NCT04876781` - Korean Post-marketing Surveillance for Xeljanz XR
Completed	`NCT03881059` - Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)	Phase 2